Effects of sulfonylureas on left ventricular mass in type 2 diabetic patients

Tsung-Ming Lee, Mei S. Lin, Chang H. Tsai, Chen-Ling Huang, Nen Chung Chang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Myocardial ATP-sensitive potassium (KATP) channels have been implicated in attenuating cardiac hypertrophy by modulating endothelin-1 concentrations. Sulfonylureas differ in their affinity for cardiac K ATP channels and therefore may vary in their effects on left ventricular (LV) mass. We sought to determine the differential effects of sulfonylureas on LV mass in type 2 diabetic patients. All patients had been taking glibenclamide for more than 3 mo before being randomized to either switch to an equipotent dose of gliclazide or continue glibenclamide. A total of consecutive 240 diabetic patients were randomized into glibenclamide, gliclazide, a combination of glibenclamide and nicorandil, or gliclazide and nicorandil for 6 mo. In the gliclazide-treated group, the LV mass index was significantly decreased compared with that in the glibenclamide-treated groups. Nicorandil administration significantly reduced LV mass in glibenclamide-treated patients compared with patients treated with glibenclamide alone. Measurements of endothelin-1 concentrations mirrored the functional status of KATP channel. Multivariate analysis revealed that regression of LV mass was significantly correlated only with the changes in endothelin-1 (P <0.0001). Our results show that KATP channels may play a pathogenetic role, probably through an endothelin-1-dependent pathway, in diabetes mellitus-related ventricular hypertrophy. Patients treated with gliclazide may have a beneficial effect in attenuating ventricular mass.

Original languageEnglish
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume292
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Glyburide
Gliclazide
KATP Channels
Endothelin-1
Nicorandil
Cardiomegaly
Hypertrophy
Diabetes Mellitus
Multivariate Analysis
Adenosine Triphosphate

Keywords

  • Adenosine 5′-triphosphate-sensitive potassium channels
  • Diabetes mellitus
  • Glibenclamide
  • Gliclazide
  • Ventricular hypertrophy

ASJC Scopus subject areas

  • Physiology

Cite this

Effects of sulfonylureas on left ventricular mass in type 2 diabetic patients. / Lee, Tsung-Ming; Lin, Mei S.; Tsai, Chang H.; Huang, Chen-Ling; Chang, Nen Chung.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 292, No. 1, 01.2007.

Research output: Contribution to journalArticle

@article{40b3120e8636489f8d93ba2115fea55e,
title = "Effects of sulfonylureas on left ventricular mass in type 2 diabetic patients",
abstract = "Myocardial ATP-sensitive potassium (KATP) channels have been implicated in attenuating cardiac hypertrophy by modulating endothelin-1 concentrations. Sulfonylureas differ in their affinity for cardiac K ATP channels and therefore may vary in their effects on left ventricular (LV) mass. We sought to determine the differential effects of sulfonylureas on LV mass in type 2 diabetic patients. All patients had been taking glibenclamide for more than 3 mo before being randomized to either switch to an equipotent dose of gliclazide or continue glibenclamide. A total of consecutive 240 diabetic patients were randomized into glibenclamide, gliclazide, a combination of glibenclamide and nicorandil, or gliclazide and nicorandil for 6 mo. In the gliclazide-treated group, the LV mass index was significantly decreased compared with that in the glibenclamide-treated groups. Nicorandil administration significantly reduced LV mass in glibenclamide-treated patients compared with patients treated with glibenclamide alone. Measurements of endothelin-1 concentrations mirrored the functional status of KATP channel. Multivariate analysis revealed that regression of LV mass was significantly correlated only with the changes in endothelin-1 (P <0.0001). Our results show that KATP channels may play a pathogenetic role, probably through an endothelin-1-dependent pathway, in diabetes mellitus-related ventricular hypertrophy. Patients treated with gliclazide may have a beneficial effect in attenuating ventricular mass.",
keywords = "Adenosine 5′-triphosphate-sensitive potassium channels, Diabetes mellitus, Glibenclamide, Gliclazide, Ventricular hypertrophy",
author = "Tsung-Ming Lee and Lin, {Mei S.} and Tsai, {Chang H.} and Chen-Ling Huang and Chang, {Nen Chung}",
year = "2007",
month = "1",
doi = "10.1152/ajpheart.00516.2006",
language = "English",
volume = "292",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "1",

}

TY - JOUR

T1 - Effects of sulfonylureas on left ventricular mass in type 2 diabetic patients

AU - Lee, Tsung-Ming

AU - Lin, Mei S.

AU - Tsai, Chang H.

AU - Huang, Chen-Ling

AU - Chang, Nen Chung

PY - 2007/1

Y1 - 2007/1

N2 - Myocardial ATP-sensitive potassium (KATP) channels have been implicated in attenuating cardiac hypertrophy by modulating endothelin-1 concentrations. Sulfonylureas differ in their affinity for cardiac K ATP channels and therefore may vary in their effects on left ventricular (LV) mass. We sought to determine the differential effects of sulfonylureas on LV mass in type 2 diabetic patients. All patients had been taking glibenclamide for more than 3 mo before being randomized to either switch to an equipotent dose of gliclazide or continue glibenclamide. A total of consecutive 240 diabetic patients were randomized into glibenclamide, gliclazide, a combination of glibenclamide and nicorandil, or gliclazide and nicorandil for 6 mo. In the gliclazide-treated group, the LV mass index was significantly decreased compared with that in the glibenclamide-treated groups. Nicorandil administration significantly reduced LV mass in glibenclamide-treated patients compared with patients treated with glibenclamide alone. Measurements of endothelin-1 concentrations mirrored the functional status of KATP channel. Multivariate analysis revealed that regression of LV mass was significantly correlated only with the changes in endothelin-1 (P <0.0001). Our results show that KATP channels may play a pathogenetic role, probably through an endothelin-1-dependent pathway, in diabetes mellitus-related ventricular hypertrophy. Patients treated with gliclazide may have a beneficial effect in attenuating ventricular mass.

AB - Myocardial ATP-sensitive potassium (KATP) channels have been implicated in attenuating cardiac hypertrophy by modulating endothelin-1 concentrations. Sulfonylureas differ in their affinity for cardiac K ATP channels and therefore may vary in their effects on left ventricular (LV) mass. We sought to determine the differential effects of sulfonylureas on LV mass in type 2 diabetic patients. All patients had been taking glibenclamide for more than 3 mo before being randomized to either switch to an equipotent dose of gliclazide or continue glibenclamide. A total of consecutive 240 diabetic patients were randomized into glibenclamide, gliclazide, a combination of glibenclamide and nicorandil, or gliclazide and nicorandil for 6 mo. In the gliclazide-treated group, the LV mass index was significantly decreased compared with that in the glibenclamide-treated groups. Nicorandil administration significantly reduced LV mass in glibenclamide-treated patients compared with patients treated with glibenclamide alone. Measurements of endothelin-1 concentrations mirrored the functional status of KATP channel. Multivariate analysis revealed that regression of LV mass was significantly correlated only with the changes in endothelin-1 (P <0.0001). Our results show that KATP channels may play a pathogenetic role, probably through an endothelin-1-dependent pathway, in diabetes mellitus-related ventricular hypertrophy. Patients treated with gliclazide may have a beneficial effect in attenuating ventricular mass.

KW - Adenosine 5′-triphosphate-sensitive potassium channels

KW - Diabetes mellitus

KW - Glibenclamide

KW - Gliclazide

KW - Ventricular hypertrophy

UR - http://www.scopus.com/inward/record.url?scp=33846252384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846252384&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00516.2006

DO - 10.1152/ajpheart.00516.2006

M3 - Article

C2 - 16936007

AN - SCOPUS:33846252384

VL - 292

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 1

ER -